Towards mitochondrial gene therapy: DQAsomes as a strategy.
Mitochondrial dysfunction is a cause, or major contributing factor in the development, of degenerative diseases, aging, cancer, many cases of Alzheimer's and Parkinson's disease and Type II diabetes (D. C. Wallace, Science 283, 1482-1488, 1999). Despite major advances in understanding mtDNA defects at the genetic and biochemical level, there is no satisfactory treatment for the vast majority of patients available. Objective limitations of conventional biochemical treatment for patients with defects of mtDNA warrant the exploration of gene therapeutic approaches. However, mitochondrial gene therapy has been elusive, due to the lack of any mitochondria-specific transfection vector. We review here the current state of the development of mitochondrial DNA delivery systems. In particular, we are summarizing our own efforts in exploring the mitochondriotropic properties of dequalinium, a cationic bolaamphiphile with delocalized charge centers, for the design of a vector suited for the transport of DNA to mitochondria in living cells.
Weissig
V
V
Department of Pharmaceutical Sciences, Northeastern University, Bouve College of Health Sciences School of Pharmacy, 211 Mugar Building, Boston, MA, 02115, USA. vweissig@hotmail.com
Torchilin
V P
VP
D000818:Animals; D004272:DNA, Mitochondrial / Q000235:genetics; D016503:Drug Delivery Systems; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008928:Mitochondria / Q000235:genetics; D017240:Mitochondrial Myopathies / Q000628:therapy*
D004272:DNA, Mitochondrial